Efanesoctocog alfa
Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency).

Efanesoctocog alfa was approved for medical use in the United States in February 2023.

Medical uses 
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.

References 

Antihemorrhagics
Recombinant proteins
Sanofi